Wyeth
1Q Revenues: $4.8 billion (+6%)
1Q Earnings: $1.1 billion (+13%)
Comments: Enbrel, Effexor, Prevnar, Premarin and Protonix drove revenue growth in the quarter. The company has rights to Enbrel outside of the U.S. and Canada where net revenue was $335 million for the quarter, up 42%. Effexor sales were $945 million, up 9%. Prevnar sales were up 10% to $432 million. Premarin product sales were $266 million for the quarter, up 26%. Protonix sales were $482 million, up 18%. R&D expenses were $684.7 million for the quarter, up +13%.
Magazine
